An open-label study of the effects of bupropion SR on fatigue, depression and quality of life of mixed-site cancer patients and their partners

Psycho-Oncology

Volumn 15, Issue 3, 2006, Pages 259-267

  Moss, Erin L ^a   Simpson, J Steven A ^a,b,c   Pelletier, Guy ^a,b   Forsyth, Peter ^a,b  

^a UNIVERSITY OF CALGARY   (Canada)

^b TOM BAKER CANCER CENTRE   (Canada)

^c Department of Psychiatry ^*  (Canada)

Author keywords

Bupropion ST treatment; Cancer; Depression; Fatigue; Quality of life

Indexed keywords

AMFEBUTAMONE;

ADULT; ARTICLE; BRAIN CANCER; BREAST CANCER; CANCER CENTER; CANCER FATIGUE; CANCER PATIENT; CAREGIVER; CASE STUDY; CLINICAL ARTICLE; CONTROLLED STUDY; DEPRESSION; DISEASE SEVERITY; DRUG EFFICACY; FEMALE; HAMILTON SCALE; HEAD AND NECK CANCER; HEMATOLOGIC MALIGNANCY; HUMAN; MALE; MALIGNANT NEOPLASTIC DISEASE; MAXIMUM TOLERATED DOSE; PATIENT REFERRAL; PHYSICAL PERFORMANCE; PSYCHOLOGIC ASSESSMENT; PSYCHOLOGICAL ASPECT; QUALITY OF LIFE; RATING SCALE; RELIGION; SCORING SYSTEM; SOCIAL ASPECT; SUSTAINED RELEASE FORMULATION; SYMPTOM; TERTIARY HEALTH CARE; TREATMENT OUTCOME; UNSPECIFIED SIDE EFFECT;

ADULT; ANTIDEPRESSIVE AGENTS, SECOND-GENERATION; BUPROPION; COHORT STUDIES; DELAYED-ACTION PREPARATIONS; DEPRESSION; DOSE-RESPONSE RELATIONSHIP, DRUG; FATIGUE; FEMALE; HUMANS; MALE; NEOPLASMS; PROSPECTIVE STUDIES; QUALITY OF LIFE; QUESTIONNAIRES; SEVERITY OF ILLNESS INDEX;

EID: 33645570691     PISSN: 10579249     EISSN: 10991611     Source Type: Journal    
DOI: 10.1002/pon.952     Document Type: Article

References (36)

1. Ahlberg K, Gaston-Johansson F, Mock V. 2003. Assessment and management of cancer-related fatigue in adults. Lancet 362: 640-650.
2. Andrykowski MA, Curran SL, Lighner R. 1998. Off-treatment fatigue in breast cancer survivors: A controlled comparison. J Behar Med 21: 1-18.
3. Broeckel JA, Jacobsen PB, Horton J, Lyman GH. 1998. Characteristics and correlates of fatigue after adjuvant chemotherapy for breast cancer. J Clin Oncol 16: 1689-1696.
4. Bruera E, Driver L, Barnes E, Willey J, Shen LJ, Palmer L, Escalante C. 2003. Patient-controlled methylphenidate for the management of fatigue in patients with advanced cancer: A preliminary report. J Clin Oncol 21: 4439-4443.
5. Burks TF. 2001. New agents for the treatment of cancer-related fatigue. Cancer 92: 1714-1718.
6. Cella D, Davis K, Breitbart W, Curt G. 2001. Cancer-related fatigue: Prevalence of proposed diagnostic criteria in a United States sample of cancer survivors. J Clin Oncol 19: 3385-3391.
7. Cleeland CS. 2000. Cancer-related symptoms. Semin Radiat Oncol 10: 175-190.
8. Cullum JL, Wojciechowski AE, Pelletier G, Simpson JSA. 2004. Bupropion SR treatment reduces fatigue in cancer patients. Can J Psychiatry 49: 139-144.
9. Duffy JD, Campbell J. 1994. Bupropion for the treatment of fatigue associated with multiple sclerosis. Psychosomatics 35: 170-171.
10. Escalante C. 2003. Treatment of cancer-related fatigue: An update. Support Care Cancer 11: 79-83.
11. Ferrell BR, Grant M, Dean GE, Funk B, Ly J. 1996. Bone tired: The experience of fatigue and its impact on quality of life. Oncol Nurs Forum 23: 1539-1547.
12. Ferrell BR, Dow KH, Grant M. 1995. Measurement of the quality of life in cancer survivors. Qual Life Res 4: 523-531.
13. Glaus A, Crow R, Hammond S. 1996. A qualitative study to explore the concept of fatigue/tiredness in cancer patients and in healthy individuals. Eur J Cancer Care (Engl) 5: S8-S23.
14. Green TR. 1997. Bupropion for SSRI-induced fatigue. J Clin Psychiatry 58: 174.
15. Goodnick PJ. 1990. Bupropion in chronic fatigue syndrome. Am J Psychiatry 147: 1091.
16. Goodnick PJ, Sandoval R, Brickman A, Klimas NG. 1992. Bupropion treatment of fluoxetine-resistant chronic fatigue syndrome. Biol Psychiatry 32: 834-838.
17. Hamilton J, Butler L, Wagenaar H et al. 2001. The impact and management of cancer-related fatigue on patients and families. Can Oncol Nurs J 11: 192-198.
18. Hamilton M. 1986. The Hamilton rating scale for depression. In Assessment of Depression, Sartorius N, Ban T (eds). Springer: Berlin, 143-152.
19. Hoffman DC. 1989. The use of place conditioning in studying the neuropharmacology of drug reinforcement. Brain Res Bull 23: 373-387.
20. Kirksey DF, Harto-Truax N. 1983. Private practice evaluation of the safety and efficacy of bupropion in depressed outpatients. J Clin Psychiatry 44: 143-147.
21. Marin RS. 1996. Apathy: Concept, syndrome, neural mechanisms, and treatment. Semin Clin Neuropsychiatry 1: 304-314.
22. Mendoza T, Wang X, Cleeland C et al. 1999. The rapid assessment of fatigue severity in cancer patients: Use of the brief fatigue inventory. Cancer 85: 1186-1196.
23. Meyers CA, Weitzner MA, Valentine AD, Levin VA. 1998. Methylphenidate therapy improves cognition, mood and function of brain tumor patients. J Clin Oncol 16: 2522-2527.
24. Mock V, Atkinson A, Barsevick A et al. 2000. NCCN practice guidelines for cancer-related fatigue. Oncology (Huntingt) 14: 151-161.
25. National Comprehensive Cancer Network. 2003. National Comprehensive Cancer Network Practice Guidelines Cancer-related Fatigue Panel 2003 Guidelines. National Comprehensive Cancer Network: Rockledge.
26. NIH state-of-the-science conference statement on symptom management in cancer: pain, depression and fatigue; 2002. http://consensus.nih.gov [Accessed November 14, 2002].
27. Reuter K, Harter M. 2004. The concepts of fatigue and depression in cancer. Eur J Cancer Care (Engl) 13: 127-134.
28. Schwartz AL, Nail LM, Chen S, Meek P, Barsevick AM, King ME. 2000. Fatigue patterns observed in subjects receiving chemotherapy and radiotherapy. Cancer Invest 18: 11-19.
29. Servaes P, Verhagen C, Bleijenberg G. 2002. Fatigue in cancer patients during and after treatment: Prevalence, correlates and interventions. Eur J Cancer 38: 27-43.
30. Settle EC, Stahl SM, Batey SR, Johnston JA, Ascher JA. 1992. Safety profile of sustained-release bupropion in depression: Results of three clinical trials. Clin Ther 21: 454-463.
31. Stone P, Ream E, Richardson E et al. 2003. Cancer-related fatigue - a difference of opinion? Results of a multicentre survey of healthcare professionals, patients and caregivers. Eur J Cancer Care (Engl) 12: 20-27.
32. Tucker WE. 1983. Preclinical toxicology of bupropion: An overview. J Clin Psychiatry 44: 60-62.
33. Vassout A, Bruinink A, Krauss J, Waldmeier P, Bischoff S. 1993. Regulation of dopamine receptors by bupropion: Comparison with antidepressants and CNS stimulants. J Recept Res 13: 341-354.
34. Weitzner MA, Jacobsen PB, Wagner H, Friedland J, Cox C. 1999. The Caregiver Quality of Life Index-Cancer (CQOLC) scale: Development and validation of an instrument to measure quality of life of the family caregiver of patients with cancer. Qual Life Res 8: 55-63.
35. Weitzner MA, Meyers CA, Valentine AD. 1995. Methylphenidate in the treatment of neurobehavioral slowing associated with cancer and cancer treatment. J Neuropsychiatry Clin Neurosci 7: 347-350.
36. Williams JB. 1988. A structured interview guide for the Hamilton Depression Rating Scale. Arch Gen Psychiatry 45: 742-747.